JP7503850B2 - シャペロン介在性オートファジー調節剤として有用なベンゾオキサゾールおよび関連化合物 - Google Patents

シャペロン介在性オートファジー調節剤として有用なベンゾオキサゾールおよび関連化合物 Download PDF

Info

Publication number
JP7503850B2
JP7503850B2 JP2021519763A JP2021519763A JP7503850B2 JP 7503850 B2 JP7503850 B2 JP 7503850B2 JP 2021519763 A JP2021519763 A JP 2021519763A JP 2021519763 A JP2021519763 A JP 2021519763A JP 7503850 B2 JP7503850 B2 JP 7503850B2
Authority
JP
Japan
Prior art keywords
phenyl
compound
chlorobenzo
oxazol
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021519763A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504650A5 (cg-RX-API-DMAC7.html
JP2022504650A (ja
Inventor
アナ・マリア・クエルボ
エヴリピディス・ガヴァシオティス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Original Assignee
Albert Einstein College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College of Medicine filed Critical Albert Einstein College of Medicine
Publication of JP2022504650A publication Critical patent/JP2022504650A/ja
Publication of JP2022504650A5 publication Critical patent/JP2022504650A5/ja
Application granted granted Critical
Publication of JP7503850B2 publication Critical patent/JP7503850B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021519763A 2018-10-10 2019-10-10 シャペロン介在性オートファジー調節剤として有用なベンゾオキサゾールおよび関連化合物 Active JP7503850B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743920P 2018-10-10 2018-10-10
US62/743,920 2018-10-10
PCT/US2019/055493 WO2020077024A1 (en) 2018-10-10 2019-10-10 Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators

Publications (3)

Publication Number Publication Date
JP2022504650A JP2022504650A (ja) 2022-01-13
JP2022504650A5 JP2022504650A5 (cg-RX-API-DMAC7.html) 2022-10-03
JP7503850B2 true JP7503850B2 (ja) 2024-06-21

Family

ID=70163886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021519763A Active JP7503850B2 (ja) 2018-10-10 2019-10-10 シャペロン介在性オートファジー調節剤として有用なベンゾオキサゾールおよび関連化合物

Country Status (11)

Country Link
US (1) US12473266B2 (cg-RX-API-DMAC7.html)
EP (1) EP3863755A4 (cg-RX-API-DMAC7.html)
JP (1) JP7503850B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210082466A (cg-RX-API-DMAC7.html)
CN (1) CN113195084B (cg-RX-API-DMAC7.html)
AU (1) AU2019358074A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021006843A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115297A1 (cg-RX-API-DMAC7.html)
IL (1) IL282069A (cg-RX-API-DMAC7.html)
MX (1) MX2021004134A (cg-RX-API-DMAC7.html)
WO (1) WO2020077024A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022015624A1 (en) * 2020-07-16 2022-01-20 Schrödinger, Inc. Substituted dihydropyrazinediones as modulators of the nmda receptor
JP2023551435A (ja) * 2020-11-20 2023-12-08 エフ. ホフマン-ラ ロシュ アーゲー B型肝炎ウイルス感染症の処置及び予防のためのn置換4-(1,3-アリールオキサゾロ-2-イル)フェニル化合物
WO2022155333A1 (en) * 2021-01-13 2022-07-21 Albert Einstein College Of Medicine Use of chaperone-mediated autophagy activators for treating or preventing blood cancers and myelodysplastic syndromes
EP4326267A4 (en) * 2021-04-21 2025-07-09 Albert Einstein College Medicine METHOD FOR INCREASING CHAPERONE-MEDIATED AUTOPHAGY BY STABILIZING THE INTERACTION BETWEEN THE RETINOIC ACID RECEPTOR ALPHA AND AN INHIBITOR
KR102778740B1 (ko) 2021-06-24 2025-03-07 주식회사 엘지화학 합성가스의 제조방법
CN114404421B (zh) * 2022-02-28 2023-04-28 同济大学 选择性自噬激活剂qx77在制备干预或治疗糖尿病视网膜病变的药物中的应用
WO2024225738A1 (ko) * 2023-04-25 2024-10-31 부산대학교 산학협력단 지방간질환 치료 또는 예방 목적의 fxr/ppar alpha 이중 작용 활성을 가지는 벤즈옥사졸 유도체 화합물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009526034A (ja) 2006-02-10 2009-07-16 スムミト コーポレーション ピーエルシー デュシェンヌ型筋ジストロフィーの治療

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH469802A (de) * 1966-01-07 1969-03-15 Ciba Geigy Verwendung von Benzoxazol-Derivaten als Scintillator-Substanzen
US5428052A (en) * 1984-09-19 1995-06-27 Centre Internationale De Recherches Dermatologiques (C.I.R.D.) Aromatic heterocyclic derivatives and their therapeutic and cosmetic use
ATE240942T1 (de) * 1995-11-17 2003-06-15 Merck & Co Inc Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren
AU2002365892A1 (en) * 2001-11-30 2003-06-17 Merck & Co., Inc. Metabotropic glutamate receptor-5 modulators
KR20040096601A (ko) 2002-02-21 2004-11-16 시바 스페셜티 케미칼스 홀딩 인크. 락탐계 안료 및 착색된 플라스틱 또는 중합체성 착색입자의 제조시 이의 용도
JP4903133B2 (ja) 2004-04-30 2012-03-28 ジェネンテック,インコーポレイティド ヘッジホッグシグナル伝達のキノキサリン阻害剤
UA91341C2 (ru) * 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
EP1954287B2 (en) 2005-10-31 2016-02-24 Merck Sharp & Dohme Corp. Cetp inhibitors
GB0602768D0 (en) * 2006-02-10 2006-03-22 Vastox Plc Treatment of muscular dystrophy
RU2462458C2 (ru) * 2006-02-10 2012-09-27 Байомарин Ига Лимитед Лечение миодистрофии дюшена
AR066879A1 (es) 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
AU2008285289A1 (en) 2007-08-03 2009-02-12 Biomarin Iga Limited Drug combinations for the treatment of Duchenne muscular dystrophy
MX2011002647A (es) 2008-09-23 2011-04-07 Wista Lab Ltd Ligandos para moleculas tau agregadas.
JP2011168515A (ja) 2010-02-17 2011-09-01 Kowa Co エリスロポエチン産生促進作用を有する2−アリールベンゾオキサゾール化合物
US9512092B2 (en) * 2013-12-12 2016-12-06 Albert Einstein College Of Medicine, Inc. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
EP3187495A1 (en) * 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
EP3431472B1 (en) * 2016-03-17 2023-05-03 Checkmate Therapeutics Inc. Novel compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same
JP2018087173A (ja) 2016-11-29 2018-06-07 国立大学法人北海道大学 悪性脳腫瘍治療薬
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
US10676467B2 (en) 2017-06-30 2020-06-09 Washington University Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009526034A (ja) 2006-02-10 2009-07-16 スムミト コーポレーション ピーエルシー デュシェンヌ型筋ジストロフィーの治療

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RN 1115890-50-0 REGISTRY,DATABASE REGISTRY [ONLINE] Retrieved from STN,2009年03月05日,検索日:14 AUG 2023
RN 1115950-78-1 REGISTRY,DATABASE REGISTRY [ONLINE] Retrieved from STN,2009年03月05日,検索日:14 AUG 2023
RN 1116042-38-6 REGISTRY,DATABASE REGISTRY [ONLINE] Retrieved from STN,2009年03月05日,検索日:14 AUG 2023

Also Published As

Publication number Publication date
MX2021004134A (es) 2021-07-16
AU2019358074A1 (en) 2021-05-06
JP2022504650A (ja) 2022-01-13
US12473266B2 (en) 2025-11-18
CA3115297A1 (en) 2020-04-16
IL282069A (en) 2021-05-31
KR20210082466A (ko) 2021-07-05
CN113195084A (zh) 2021-07-30
EP3863755A4 (en) 2022-08-03
BR112021006843A2 (pt) 2021-07-13
US20210387953A1 (en) 2021-12-16
CN113195084B (zh) 2024-04-09
EP3863755A1 (en) 2021-08-18
WO2020077024A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
US12473266B2 (en) Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators
CN105682656B (zh) 调节法尼醇x受体的组合物和方法
JP5271895B2 (ja) 抗糖尿病性の二環式化合物
JP7591066B2 (ja) Lpa受容体アンタゴニスト及びそれらの使用
JP7099672B2 (ja) 医薬化合物
JP7691522B2 (ja) Lpa受容体アンタゴニスト及びそれらの使用
JP7262141B2 (ja) シャペロン介在性オートファジー調節剤として有用な化合物
JP2013531644A (ja) βセクレターゼ(BACE)の阻害剤として有用な5−アミノ−3,6−ジヒドロ−1H−ピラジン−2−オン誘導体
TW201625533A (zh) Kcnq 2至5通道活化劑
TW202540086A (zh) 一種多環類衍生物、其製備方法和應用
TW201925154A (zh) 苯並雜環衍生物及包含其的醫藥組合物
IE911310A1 (en) Antiinflammatory hydroxamic acids and N-hydroxyureas
JP6937524B2 (ja) アミド化合物およびその使用
JP4842963B2 (ja) 糖尿病を処置するdpp−iv阻害剤としての置換ベンゾキノリジン
CN104363903A (zh) 用作蛋白聚集抑制剂的苯基脲和苯基氨基甲酸盐/酯衍生物
CA2874400A1 (en) Tricyclic compounds as kat ii inhibitors
CN108239029A (zh) 一类四氢异喹啉化合物及其盐的制备和医药用途
WO2025146650A1 (en) Modulators of intracellular chloride concentration
KR20080075922A (ko) 칼슘 채널 차단제로서의 디벤젠 유도체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220922

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240604

R150 Certificate of patent or registration of utility model

Ref document number: 7503850

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150